Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

450
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
450
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

141
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
141
Liver Physiology01:30

Liver Physiology

419
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
419
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

77
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
77

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The persistent challenge of diagnosing and treating vitamin B<sub>12</sub> deficiency.

BMJ (Clinical research ed.)·2024
Same author

Chronic Kidney Disease: Prevention, Diagnosis, and Treatment.

American family physician·2024
Same author

Pulmonary Nodules: Common Questions and Answers.

American family physician·2023
Same author

Scrotal Masses.

American family physician·2022
Same author

Adult Eye Conditions: Ophthalmic Emergencies.

FP essentials·2022
Same author

Hepatitis A.

American family physician·2021

Related Experiment Video

Updated: Jun 4, 2025

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

11.2K

Mildly Elevated Liver Transaminase Levels: Causes and Evaluation.

Robert C Langan1, Kourtni A Hines-Smith1

  • 1St. Luke's Family Medicine Residency-Sacred Heart Campus, Allentown, Penn.

American Family Physician
|December 19, 2024
PubMed
Summary
This summary is machine-generated.

Elevated liver enzymes, aspartate and alanine transaminases, affect 10-20% of people. Common causes include metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol, with lifestyle changes crucial for management.

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

9.9K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

2.4K

Related Experiment Videos

Last Updated: Jun 4, 2025

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

11.2K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

9.9K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

2.4K

Area of Science:

  • Hepatology
  • Internal Medicine
  • Biochemistry

Background:

  • Elevated liver chemistry levels, including aspartate and alanine transaminases, are observed in 10-20% of the general population.
  • These elevations can indicate significant liver disease and are linked to increased mortality risk.
  • Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease are the most frequent causes of mildly elevated transaminases.

Purpose of the Study:

  • To outline the common and uncommon causes of elevated transaminase levels.
  • To describe initial laboratory testing and diagnostic approaches for liver disease.
  • To emphasize lifestyle modifications and potential fibrosis assessment in managing elevated liver enzymes.

Main Methods:

  • Review of common, uncommon, and rare causes of elevated transaminases.
  • Description of initial laboratory investigations including blood counts, metabolic panels, and viral hepatitis screening.
  • Mention of fibrosis scoring systems like FIB-4 and NAFLD Fibrosis Score for MASLD assessment.

Main Results:

  • MASLD and alcoholic liver disease are the primary drivers of mildly elevated transaminases.
  • A range of conditions, from hepatitis B/C and hemochromatosis to autoimmune diseases and extrahepatic causes, can also lead to elevated levels.
  • Initial tests guide further investigation, with fibrosis scores aiding in risk stratification for MASLD.

Conclusions:

  • Prompt identification and management of elevated transaminases are essential due to their association with liver disease and mortality.
  • Lifestyle interventions such as alcohol moderation, weight loss, and avoiding hepatotoxic drugs are fundamental.
  • Further investigation and specialist referral are indicated for patients at risk of significant liver fibrosis.